To embed, copy and paste the code into your website or blog:
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Mayo Foundation for Medical Education and Research v. ARUP Laboratories, Inc.
0:13-cv-00933; filed April 22, 2013 in the District Court of Minnesota
Infringement of U.S. Patent Nos. 7,700,365 ("Vitamin D Deficiencies," issued April 20, 2010), 7,901,944 (same title, issued March 8, 2011), and 8,349,613 ("Mass Spectroscopy Techniques for Detecting Vitamin D Compounds in a Sample," issued January 8, 2013) based on ARUP's diagnostic testing referred to as "25-Hydroxyvitamin D2 and D3 by Tandem Mass Spectrometry." View the complaint here.
Bioniche Life Sciences, Inc. v. Rea
1:13-cv-00491; filed April 22, 2013 in the Eastern District of Virginia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,293,745 ("Use of Imatinib to Treat Liver Disorders and Viral Infections," issued October 23, 2012). View the complaint here.
Precision Biosciences Inc. et al. v. Lonza Group Ltd. et al.
1:13-cv-00708; filed April 19, 2013 in the District Court of Delaware
• Plaintiffs: Precision Biosciences Inc.; Duke University
• Defendants: Lonza Group Ltd.; Lonza Sales Ltd.; Lonza Biologics plc; Lonza Inc.; Lonza Walkersville Inc.; Lonza Biologics Inc.
Infringement of U.S. Patent No. 8,377,674 ("Method for Producing Genetically-Modified Cells with Rationally-Designed Meganucleases with Altered Sequence Specificity," issued February 19, 2013) based on Lonza's manufacture, use, and sale of certain products, including the GS XceedTM Gene Expression System and CHOK1SV GS knock-out host cell. View the complaint here.
Pfizer Inc. et al. v. Inventia Healthcare Private Ltd.
1:13-cv-02986; filed April 19, 2013 in the Northern District of Illinois
• Plaintiffs: Pfizer Inc.; Pharmacia & Upjohn Co. LLC; Pfizer Health AB
• Defendant: Inventia Healthcare Private Ltd.
Infringement of U.S. Patent Nos. 6,630,162 ("Pharmaceutical Formulation and Its Use," issued October 7, 2003) and 6,770,295 ("Therapeutic Formulation for Administering Tolterodine with Controlled Release," issued August 3, 2004) following a Paragraph IV certification as part of Inventia's filing of an ANDA to manufacture a generic version of Pfizer's Detrol LA® (extended release tolterodine tartrate, used to treat overactive bladder). View the complaint here.
Helsinn Healthcare SA et al. v. Aurobindo Pharma Ltd. et al.
1:13-cv-00688; filed April 16, 2013 in the District Court of Delaware
• Plaintiffs: Helsinn Healthcare SA; Roche Palo Alto LLC
• Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc.
Infringement of U.S. Patent Nos. 7,947,724 ("Liquid Pharmaceutical Formulations of Palonosetron," issued May 24, 2011), 7,947,725 (same title, issued May 24, 2011), and 7,960,424 (same title, issued June 14, 2011) following a Paragraph IV certification as part of Aurobindo's filing of an ANDA to manufacture a generic version of Helsinn's Aloxi® (palonosetron hydrochloride intravenous solution, used to prevent chemotherapy induced nausea and vomiting). View the complaint here.
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© McDonnell Boehnen Hulbert & Berghoff LLP
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up to create your digest using LinkedIn*
Back to Top